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The spacesuit assembly has a fascinating and complicated history dating back to the 
early 1930s. Much has been written on this history from an assembly perspective and, to a 
lesser extent, a component perspective. However, little has been written or preserved 
specifically on smaller, lesser-known aspects of pressure suit design. One example of this is 
the injection patch—a small 2–in.-diameter disk on the leg of the Apollo suit that facilitated 
a medical injection when pressurized, and the only known implementation of such a feature 
on a flight suit. Whereas many people are aware this feature existed, very little is known of 
its origin, design, and use, and the fact that the Apollo flight suit was not the only instance in 
which such a feature was implemented. This paper serves to tell the story of this seeming 
“afterthought” of a feature, as well as the design considerations heeded during the initial 
development of subsequent suits. 
Nomenclature 
EMU = Extravehicular Mobility Unit 
ETFE = ethylene tetrafluoroethylene 
EVA = extravehicular activity 
FEP = fluorinated ethylene propylene 
ILC = International Latex Corporation 
IM = intramuscular (injection) 
IO = intraosseal (injection) 
IV = intravascular (injection) 
LCG = liquid cooling garment 
NASA = National Aeronautics and Space Administration 
PGS = pressure garment subsystem 
TMG = thermal micromediorite garment 
UTC = urine transfer connector 
I. Introduction 
he earliest efforts in pressure suit design were driven by the need to survive high altitudes during attempts to 
break speed or height flight records. At first, these efforts were propelled by daredevil aviators such as Wiley 
Post; however, the most aggressive pressure suit development period arguably occurred between the early 1940s and 
the mid 1960s, beginning with parallel and often competing efforts funded by the US Air Force and the US Navy, 
and culminating in the design of the Apollo Extravehicular Mobility Unit (EMU).  
Although differences abound between early flight suits and spacesuits used during the Mercury and Gemini 
programs, one common factor differentiates them from the Apollo suit: For Apollo, the ability to get back to the 
safety of Earth relatively quickly was precluded. The fact that Apollo represented a change from being able to get 
home within hours to not being able to get home for days drove the program to consider additional risks, and the 
requirements to address those risks.   
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Based on the Apollo Block 1 Spacesuit Assembly, Model A-1C Technical Manual,3 the injection patch was 
added on version A-1C-6 (Fig. 3). Based on this information, Cathy Lewis at the Smithsonian Institute performed a 
comprehensive survey of the 15 David Clark A-1C suits in their possession. Of these, 11 suits were available for 
evaluation; of these, 10 suits had injection patches intact (Fig. 4). Interestingly enough, although they were 
constructed and integrated similar to 
the ILC A7L injection patches (as 
illustrated in the next section), there 
are varying levels of integration. For 
example, compare the injection 
patches from A-1C serial number 
114 to serial numbers 133 and 125. 
Whereas serial numbers 114 and 
125 were well integrated to the back 
side of the cover layer using different 
applications of loop tape, serial 
number 133 has exposed Link-Net 
and bladder. As this injection 
hardware was likely never designed 
to be tested, it is of little consequence 
as far as safety is concerned, but it 
does provide interesting insight into 
the varied construction methods that 
were tried across different assemblies 
within a relatively short period of 
time. 
It should be mentioned that little 
else is known, with certainty, regarding these injection discs—e.g., what material they were made of, if they were 
tested, etc. However, it can be said with some confidence that other than the ILC design that flew for Apollo, the 
David Clark A-1C is the only other known pressure suit with a functional injection patch. 
 
Figure 2. X-ray image of David Clark  A-1C suit. Source: Smithsonian Institute Image 2009-0965. 
 
Figure 3. Text Excerpt noting addition of injection hardware to 
David Clark A-1C. Source: Apollo Block 1 Spacesuit Assembly, 
Model A-1C Technical Manual, November 1, 1965.  
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IV. Apollo Injection Hardware 
 
Specific details on the engineering design of the 
Apollo medical injector are scarce. Engineering 
drawings, specifications, requirements, or internal 
pictures of the devices have not been found. Several of 
the injectors are on display at the Smithsonian 
National Air and Space Museum in Washington D.C., 
but the internal structure of these injectors has not 
been examined. Pictures of the medical kit and the 
injectors are shown in Figs. 13 and 14. 
Several people who had first-hand experience of 
the Apollo design were contacted during the course of 
the search for information. Dr. Sam Pool joined 
NASA in 1969 and served as a flight surgeon during 
the Apollo Program. From his description, the 
injectors housed pre-filled medical syringes inside a 
pressurized aluminum tube. This tube was placed flush 
with the outside of the resraint layer, and was 
activiated by pressing a button at the top of the 
device. Once the button was depressed, a 
spring performed two actions. First, the 
syringe and needle were displaced, driving the 
needle through the seal on the device, through 
the injection patch in the EVA suit, and into 
the muscle on the upper thigh. The spring 
continued its action to depress the plunger on 
the syringe, delivering the medication into the 
muscle of the crewmember. The time from 
depressing the button on the injector to 
complete delivery of the medication was fast 
(less than 1 second) to prevent the 
crewmember being injected from reflexively 
pulling away before the injection was finished. 
 
 
V. Post-Apollo Development 
Likely due to the operational concept of the the Space Shuttle Program, the Shuttle EMU did not carry an 
injection patch; therefore, development of in-suit injection hardware languished for the better part of 4 decades. 
However, with the Constellation Program looking to enable a human lunar return came a renewed interest and the 
need to provide injection capability through the suit. 
Most of the development during the Constellation suit project focused on risk and requirements definition. 
Looking at this work provides a microcosm of the different risk posture of the Constellation Program as compared to 
the Apollo Program. For example, one of the largest driving contingency scenarios defined in Constellation was the 
so-called “144-hour return” case, where a pressurized suit would need to protect its occupant from the lunar surface 
and all the way back to Earth during a contingency. In theory, this is no different from the Apollo risk; however, the 
Constellation Program set out to specifically protect for this scenario. Driving requirements included 144 hours of 
in-suit waste management, 144 hours of nutrition and hydration, and 144 hours of emergency medical care. 
Regarding the latter, Constellation Medical Operations identified a list of possible medical scenarios needing 
protection during this contingency return. Among the scenarios was the pushing of fluids in the event the 
crewmember became ill and was unable to maintain hydration using a feeding tube (Fig. 15).   
 
Figure 13.  Apollo Medical Kit.  Six injectors shown. 
 
Figure 14. Motion Sickness Injector from Apollo Medical  
Kit. Other injectors labeled: XXX. 
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This quickly became an issue, as previous implementations of in-suit injection patches were meant for 
instramuscular (IM) injections. To push fluids, either an intravascular (IV) or intraosseal (IO) injection would be 
required. The former would likely need a permanently installed IV in the crewmember, something not considered 
practical or acceptable, especially for something meant to be used only in a contingency; the latter would require an 
injection directly into the bone—relatively difficult and painful as compared to an IM injection. On top of that, 
imposing IO injections limited the candidate injection sites to only a handful of locations. However, for a short time 
during development, IO injection was a requirement levied on the Constellation suit (along with the IM injection 
requirement). 
In assessing the feasability of meeting the above requirements, engineers identified three candidate locations for 
the IO injection patch: the proximal tibial (knee), the distal tibial (ankle), and the proximal humerus (shoulder). 
However, none of these locations were attractive from a suit design perspective as they are all areas limited in real 
estate, taken up by important mobility elements. In the end, the IO injection requirement was removed, and a 
definite location was never identified. 
Similarly, little development occurred on the IM injection patch before it was removed from the requirement set 
with a reduction in scope to an International Space Station-based mission. Plans were to leverage experience gained 
from the Apollo legacy design and perhaps update with new materials. Due to the flexibility of IM injection sites, no 
location was ever identified. However, for ease of pressurized use and the need for a crewmember to inject 
himself/herself as well as others, the injection site likely would have been placed on the thigh, similar to the Apollo 
design. 
Prior to the removal of the injection requirements, limited work was completed to determine the most effective 
way of delivering liquid medication through the spacesuit to an injured or ill crewmember. Limited testing was 
completed on the suit side to determine what types of materials would work best to ensure an adaqate seal after 
injection. The main component of the Apollo-era injection patches was silcone, which is also the main component of 
medicinal vial caps. The project obtained different silcone materials in varying thicknesses and coatings. A needle 
was attached to a force gauge, and the septa material was punctured numerous times to evaluate the ingretity of the 
 
 
Figure 15. Constellation Program Injection requirements (Constellation Space Suit Element Elements 
Requirement Document5 [CSSE]). Both instramuscular (IM) and intraosseal (IO) requirements were 
originally considered. 
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seal. Testing was performed on the benchtop in ambient conditions, in a vacuum environment, and in a cold 
chamber. After this testing, NASA concluded that the septum used for a suit interface should be either a fluorinated 
ethylene propylene (FEP [Teflon® FEP] or an ethylene tetrafluoroethylene (ETFE [Tefzel ®]) coated silicone septum 
with a thickness of 0.075” or greater. 
 
 
In addition to testing of the septa materials, the team performed work to determine optimal parameters for the 
syringe. The design of an injection device for continegency space operations presents many challenges. Among 
them are how to maintain the temperature and pressure of the liquid medication without an operational 
environmental control and life support system. Also, with the crewmembers in their EVA suits during the 
contingency, what is the best form for the injector to take for ease of use. The EVA gloves inhibit dexterity and 
motion; in an emergency medical situation, the injector needs to be simple to operate. Testing was performed in a 
flight glove simulator to examine this parameter. The testing consisted of simulating operation of various forms and 
sizes of syringes to determine ease of operation while wearing pressurized EVA gloves. Using three different test 
operators, a 0.87-in.-diameter syringe was unanimously agreed upon to be the easiest syringe to operate with a 
gloved hand. This helped constrain the possible geometries for future injection devices. 
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Figure 16. Gloved assessment of syringes. Different syringes were manipulated with EVA gloves in a 
simulated pressure environment to determine how the geometry and size of a potential injection device affects 
a gloved operator’s ability to provide an injection. 
